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Background: Targeted next generation sequencing (tNGS) has become part of molecular pathology diagnostics for
determining RAS mutation status in colorectal cancer (CRC) patients as predictive tool for decision on EGFR-targeted
therapy. Here, we investigated mutation profiles of case-matched tissue specimens throughout the disease course of
CRC, to further specify RAS-status dynamics and to identify de novo mutations associated with distant metastases.
Methods: Case-matched formalin-fixed and paraffin-embedded (FFPE) resection specimens (n = 70; primary tumours,
synchronous and/or metachronous liver and/or lung metastases) of 14 CRC cases were subjected to microdissection of
normal colonic epithelial, primary and metastatic tumour cells, their DNA extraction and an adapted library protocol for
limited DNA using the 48 gene TruSeq Amplicon Cancer PanelTM, MiSeq sequencing and data analyses (Illumina).
Results: By tNGS primary tumours were RAS wildtype in 5/14 and mutated in 9/14 (8/9 KRAS exon 2; 1/9 NRAS Exon 3)
of cases. RAS mutation status was maintained in case-matched metastases throughout the disease course, albeit with
altered allele frequencies. Case-matched analyses further identified a maximum of three sequence variants (mainly in
APC, KRAS, NRAS, TP53) shared by all tumour specimens throughout the disease course per individual case. In addition,
further case-matched de novo mutations were detected in synchronous and/or metachronous liver and/or lung
metastases (e.g. in APC, ATM, FBXW7, FGFR3, GNAQ, KIT, PIK3CA, PTEN, SMAD4, SMO, STK11, TP53, VHL). Moreover, several
de novo mutations were more frequent in synchronous (e.g. ATM, KIT, PIK3CA, SMAD4) or metachronous (e.g. FBXW7,
SMO, STK11) lung metastases. Finally, some de novo mutations occurred only in metachronous lung metastases
(CDKN2A, FGFR2, GNAS, JAK3, SRC).
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Conclusion: Together, this study employs an adapted FFPE-based tNGS approach to confirm conservation of RAS
mutation status in primary and metastatic tissue specimens of CRC patients. Moreover, it identifies genes preferentially
mutated de novo in late disease stages of metachronous CRC lung metastases, several of which might be actionable by
targeted therapies.
Keywords: Colorectal cancer, Next generation sequencing, Metastases, FFPEBackground
Predictive molecular pathology mutation testing in se-
lected genes is a routine diagnostic application in several
epithelial tumour entities. This includes extended RAS
testing (KRAS and NRAS exons 2,3,4) in advanced
colorectal cancer (CRC) patients, which functions as
well-established predictive biomarker for resistance to
EGFR-targeted therapy (e.g. cetuximab or panitumumab)
[1–5]. In addition, BRAF mutation testing is recom-
mended for molecular grading of undifferentiated CRCs
or as supportive tool for further molecular classification
of microsatellite-instable CRCs [6].
Whilst dideoxy-Sanger sequencing, pyrosequencing or
quantitative polymerase chain reaction-based assays
were routinely used in the past, targeted next generation
sequencing (tNGS) has by now evolved as a robust,
time- and cost-efficient technique to accommodate the
growing demand for mutation profiling in molecular
pathology laboratories. Indeed, there are increasing
numbers of reports on the general reliability and applic-
ability of tNGS for mutation analyses of formalin-fixed
and paraffin-embedded (FFPE) tissue specimens and/or
the generation of tumour-entity specific tNGS gene
panels, using different platforms and library preparation
approaches [7–12]. In addition, several investigators com-
pared primary colon and/or rectal tumours and metasta-
ses by NGS approaches in cohorts of 13 cases [13], 15
cases [14], 18 cases [15], 20 cases [16], 24 cases [17], 34
cases [18] or >400 cases [19]. These studies were based on
fresh-frozen tissue specimens [15] or assessment of FFPE
tissue specimens by amplicon-based semi-conductor NGS
technology [13, 16, 17, 19], or evaluation of fresh-frozen
tissue specimens with >70 % tumour cell content by whole
exome sequencing [14, 18]. Reference to the otherwise
mostly small tissue specimens and limited tumour cells of
CRC liver or lung metastases in NGS performance and
data interpretation is still sparse. Moreover, few of the
previous studies focused on the individual clinico-
pathological and molecular characteristics of the investi-
gated cases. One study [13] performed tNGS data analysis
of 13 matched pairs of the primary tumour plus each one
liver metastasis, reporting a 78 % match of mutations. In
another study using semi-conductor NGS technology,
mutations in for example APC, KRAS, FBXW7, PIK3CA,
BRAF, SMAD4 were concordant between primary CRCsand their metastases, whereas 4 of 24 cases also showed
de novo mutations in SYNE1, CTNNB1, TP53 and PTEN
[17]. Similar findings were found in another study, which
examined 17 paired primary and mainly synchronous meta-
static CRC tissue specimens in a >400 CRC cohort [19]. In
two whole exome sequencing based studies [14, 18], muta-
tion profiles of key CRC associated genes were similar in
primary and metastatic tumours by 53 % [14] and 57 %
[18], with additional de novo mutations in metastases of
47 % [14] and 43 % [18]. No correlations of case-matched
tumour specimens to clinico-pathological and molecular
characteristics were made.
Taken together, there is hence still a lack of studies which
address the question of mutation profiles of CRC tumour
progression based on case-matched tissue specimen analyses
by another NGS platform using limited numbers of micro-
dissected tumour cells, and case-matched data analyses
reflecting the individual clinico-pathological and molecular
characteristics of CRCs.
In this study, we therefore established a sequencing-by-
synthesis targeted NGS approach for analysis of 48 genes
in limited numbers of tumour cells microdissected from
different types of FFPE tissue specimens. We applied this
approach to study mutation profiles of 14 CRC cases with
70 matched tissue specimens from primary tumours and
corresponding synchronous and metachronous liver and/
or lung metastases. We took into account clinical (treat-
ment regimens, disease course, e.g. synchronous and meta-
chronous metastases), pathological (e.g. primary tumour
location, histotype) and molecular (e.g. microsatellite-
status, CpG island methylator phenotype) parameters. By
this approach, we confirm conservation of predictive RAS
mutation status throughout the disease course and identify
de novo mutations associated with either synchronous or
metachronous lung metastases.
Methods
Patients and tissue specimens
For establishing the novel tNGS approach, matched
Fresh-Frozen (FF) and Formalin-fixed and Paraffin-
embedded (FFPE) tissue specimens of 3 non-small cell
lung, breast and colorectal carcinomas were selected as
technical testing cohort. For further validation, FFPE tis-
sue specimens of two breast cancers (n = 4 histologic le-
sions) and two CRC cases (n = 7, including normal
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were selected as technical validation cohort (Additional
file 1: Text S1, Table S1).
For analysis of case-matched disease course tissue
specimens of CRC patients, FFPE tissue specimens were
obtained from 14 CRC patients with synchronous and/
or metachronous liver and/or lung metastases (total 70
tissue specimens) undergoing surgery at the Medical
Center - University of Freiburg, Germany. In case of
multiple lesions at one surgically addressed disease time
point (e.g. two lesions in distinct liver segments or two
lesions of lung metastases in the right and left lung),
these were analyzed individually. Processed tissue
specimens hence included normal colonic epithelium
dissected from the tumour-free resection margins,
primary tumours derived from central tumour areas of
resection specimens as well as metastatic liver or lung
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Fig. 1 Clinico-pathological data of the colorectal carcinoma patient cohort
resected primary tumours and synchronous or metachronous liver or lung
presents the 70 tissue specimens analyzed from the 14 CRC cases according to p
yellow= synchronous liver metastases, light green = synchronous lung metastase
metastases, pink boxes = treatment regimens, black = death of patient. Refer to m
year”; neoadj. RTCx = neoadjuvant radio-/chemotherapyre-classified and marked by a qualified pathologist (LL) for
microdissection and tumour cell content on newly pre-
pared H&E sections serial to those for microdissection.
Definition of synchronous versus metachronous me-
tastases was according to resection with > 6 months post
primary tumour resection. Clinico-pathological parame-
ters - including treatment regimens - of the cases are
given in Fig. 1 and Table 1. Note that rectal carcinomas
receiving neoadjuvant chemotherapy prior to resection
of the primary tumors (4/5 cases) are hence classified
with “ypTNM”. Note also that different treatment regi-
mens were given to each case throughout the individual
complex disease courses. Therefore, unless otherwise
specified, data was analyzed in truly case-matched
approach addressing each individual patient.
The use of tissue specimens had been approved by the
local ethics Institution (#251/04, #66/07 and #191/13,
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. a The table graph displays the time course and occurrence of
metastases included in the study from 14 patients. b The diagram
rimary tumour site, classification and metastases. Blue = primary tumours,
s, orange =metachronous liver metastases, dark green =metachronous lung
ain text and Table 1 for further clinico-pathological data. Q1-Q4 = “quarterly
Table 1 Summary of the clinico-pathological data of the colorectal cancer patient cohort
Case ID# Gender Age Location Date resected Tissue specimens Sample ID # T Number Histo-type G MSI CIMP Treatment
1 m 71 Colon right 03/04 NO 1 Ardalan
03/04 PT 2 pT3 pN1 (3/20) NOS G3 neg neg
05/04 synM[HEP] 3
04/08 metM[PUL] 5
2 f 65 Rectum 12/09 NO 6 Not available













4 m 64 Rectuma 04/05 NO 21 FOLFOX, 5-FU/Mitomycin,
FOLFIRI




5 f 57 Colon left 10/12 NO 28 3x FOLFOXIRI/Bevacizumab




6 f 67 Colon left 03/06 NO 34 3x FOLFIRI/Bevacizumab,
FOLFOX













Table 1 Summary of the clinico-pathological data of the colorectal cancer patient cohort (Continued)
7 f 35 Colon left 07/07 NO 40 FOLFOX4





8 f 50 Colon left 07/10 NO 54 FOLFOXIRI, FOLFOXIRI/
Bevacizumab




9 f 62 Colon left 07/05 NO 61 Xeloda





10 m 51 Rectuma 01/04 NO 70 RCTx
01/04 PT 71 ypT3 ypN0 (0/15) NOS G2 neg neg
10/05 metM[HEP] 73
02/09 metM[PUL] 74
11 f 44 Rectuma 12/07 NO 75 FOLFIRI/Bevacizumab




12 m 48 Rectuma 01/11 NO 87 RCTx, Xeloda, FOLFIRI/
Bevacizumab,














Table 1 Summary of the clinico-pathological data of the colorectal cancer patient cohort (Continued)
13 m 61 Colon left 09/03 NO 94 Not available




14 m 67 Colon right 02/14 NO 100 2x FOLFOXIRI/Bevacizumab,
FOLFIRI/Bevacizumab




No normal colonic epithelium, PT primary tumour, synM[HEP] synchronous liver metastasis, metM[HEP] metachronous liver metastasis, synM[PUL] synchronous lung metastasis, metM[PUL] metachronous lung metastasis
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For fresh-frozen tissue specimens, 10 to 20 μm serial
sections were cut from each tissue specimen for manual
microdissection of normal or tumour cells under morpho-
logical control, respective microscope using fine needles.
DNA isolation was with the QIAamp Micro Kit, according
to the manufacturer’s protocol (Qiagen, Hilden, Germany).
For FFPE tissue specimens, 5 to 10 μm serial sections
were cut from each tissue specimen for manual microdissec-
tion of normal or tumour cells under morphological control,
respective microscope using fine needles. From the testing
and validation tissue specimens, DNA isolation was with the
QIAamp FFPE DNA Kit, according to the manufacturer`s
protocol (Qiagen, Hilden, Germany). For the disease course
CRC tissue specimens, DNA was isolated using the Allprep
DNA/RNA FFPE Kit according to the manufacturer’s in-
structions (Qiagen, Hilden, Germany).
For each sample, DNA concentration and purity was
determined using the Nanodrop-8000 (ND1000, Peqlab,
Erlangen, Germany) and the DNA quality was measured
in triplicate using the “FFPE QC Kit” according to the
manufacturer`s protocols (Illumina, San Diego, USA).
For the latter, the average difference of Cycle-treshold
(Ct) values between the DNA samples and a positive
DNA control were calculated as relative “QC value”,
with “<2” suggested as a valid DNA sample for library
preparation by the manufacturer.
MSI and CIMP analyses of CRC tissue specimens
For MSI testing, a previously published multiplex PCR
protocol was used with slight modifications [20]. The CpG
island methylator phenotype (CIMP) status was determined
by pyrosequencing addressing methylation of five CIMP-
related genes (RUNX3, CACNA1G, EPM2AIP1/MLH1,
NEUROG1,CRABP1) with modifications to previously pub-
lished protocols [21–23].
Library preparation and sequencing
Initially, libraries of the technical testing cohort were pre-
pared with the TruSeq Amplicon Cancer Panel (TSACP),
covering 225 amplicons of 48 cancer associated genes,
following exactly the manufacturer’s protocol (Illumina,
San Diego, USA). Since this did not yield reliable libraries
for the different types of FFPE tissue specimens (Additional
file 1: Table S1A), modifications to the library protocol were
made to the first hybridization step with oligo pools and to
subsequent PCR cycling parameters (see Additional file 1:
Table S1B). The comparison of the performance of these
different library protocols is presented for the technical
testing and validation cohorts (Additional file 1: Figure S1).
The selection of specific library protocols according to
DNA amount and quality for the 70 DNA samples of
the CRC study cohort is provided together with the
tumour cell content in Additional file 1: Table S2).Libraries were examined for quantity and quality using
the Bioanalyzer 2100 system (Agilent Technologies, Santa
Clara, USA) and subjected to clean up, normalization and
pooling according to the manufacturer (Illumina, San
Diego, USA). MiSeq sequencing runs were performed
with each 16–20 pooled libraries using the MiSeq Reagent
Kit v2 (300 cycle) (Illumina, San Diego, USA) and paired-
end sequencing with 2 × 151 bp.
Targeted NGS data analysis and validation of detected
variants
Established software tools associated with MiSeq technology
were used, including Real Time Analysis, MiSeq Reporter
analysis and VariantStudio (all Illumina, San Diego, USA).
For variant filtering, a 10 % cut-off of allele frequency, with
exclusion of synonymous variants and those at a population
frequency >5 % (i.e. common sequence variants in KDR
p.Q472H, KIT p.M541L and TP53 p.P72R are not reported
in text, tables and figures) were used. The Integrative Gen-
omics Viewer (IGV; Broad Institute, UK) [24, 25] was used
to visualize read alignments and presence of variants against
the reference genome (hg39).
Data sets of normal colonic epithelium were sub-
tracted from those of case-matched tumour (primary,
metastases), yielding somatic sequence variants exclu-
sively. De novo mutations in metastases were obtained
by subtracting the primary tumour data sets from those
of case-matched metastases. All detected sequence vari-
ants are provided in Additional file 2: Table S4.
Validation of selected somatic variants was done for 27
DNA samples of 8 CRC cases by dideoxy sequencing ac-
cording to SOP-driven molecular pathology protocols or
for TP53 as described previously [26] (Additional file 1:
Table S3). All primer sequences are available upon request.
Results
Establishment of library preparation from DNA samples
derived from different origin tissue specimens
We first tested the standard tNGS library protocol for
different types of matched fresh-frozen (FF) and FFPE
tissue specimens from a technical testing cohort of 3
pairs of non-small-cell lung (NSCLC), colorectal (CRC)
and breast carcinomas (Additional file 1: Figure S1A,
Table S1A). To allow tNGS analysis also from low input
and poorer DNA quality, we adapted the library proto-
col (oligo hybridization, PCR cycling conditions) using
DNA samples derived from a technical validation co-
hort of FFPE tissue specimens of two CRC cases (n = 7,
including normal epithelium, primary tumour, liver or
lung metastases) and two breast carcinomas (n = 4, dif-
ferent histologic lesions) (Additional file 1: Figure S1B,
Table S1B).
Thereby, modification of the library protocol allowed
analysis of different types of FFPE tissue specimens,
Kovaleva et al. Molecular Cancer  (2016) 15:63 Page 8 of 19including those with limited DNA amounts from few mi-
crodissected tumour cells. Hence, this also enables ana-
lysis of limited viable tumour cells from CRC tissue
specimens post neoadjuvant therapy or from liver metas-
tases with marked necrosis.
Targeted NGS of CRC cases with longitudinal disease
course tissue specimens
We next applied the new tNGS approach to profile the
tissue specimens obtained throughout the individual dis-
ease course of 14 CRC patients, each case presenting
with specific clinico-pathological parameters, which
were included in tNGS data evaluation and interpret-
ation. From each case, normal epithelium, primary
tumour and at least two distant metastases were selected
for mutation profiling, resulting in n = 70 DNA samples
in total (Fig. 1, Table 1, Additional file 1: Table S2).
As expected from the size and histology of the lesions
of primary tumour and metastatic sites (Fig. 2a), the
DNA samples derived from the microdissected tumour
cells showed a wide range of DNA concentrations (5 to
452 ng/μl, reflecting the maximum DNA of enriched
tumour cells from the partially small tissue specimens of
metastatic lesions; mean tumour cell content of enriched
samples = 69 %, with 4 DNA samples from cases #1, #6,
#13 showing only 10–30 % tumour cell enrichment;
Additional file 1: Table S2) and quality scores (QC range
0.1 to 3, with a QC value >2 in 24/70 DNA samples),
therefore requiring adjusted tNGS library preparation ac-
cording to the newly established protocols (Additional file
1: Table S2). Thereby, all 70 DNA samples yielded
sufficient libraries, resulting in mean amplicon coverage of
5767x (range 1003x to 9517x) upon sequencing (Fig. 2b).
With a cut-off of 10 % allele frequency for variant call-
ing, the most frequently mutated genes, respective se-
quence variants occurring in at least 2 tissue specimens
of primary tumour and/or liver and/or lung metastases
were: TP53 (10/14 cases), APC (8/14 cases), KRAS (8/14
cases), SMAD4 (2/14 cases) as well as FGFR3 (1/14
cases) and PIK3CA (1/14 cases) and NRAS (1/14 cases)
(Table 2). See also Additional file 2: Table S4 for all de-
tected sequence vairants.
RAS mutation status is maintained in case-matched
primary CRCs and their metastatic sites
We next examined the RAS status throughout the dis-
ease course of the individual CRC cases.
Of the 14 cases, 8/14 (57 %) exhibited KRAS (exon 2,
codon 12 or 13) mutations in the primary tumour and
1/14 (7 %) a NRAS (exon 3, codon 61) mutation
(Table 3). These RAS mutations were detectable
throughout the disease course in each resected tumour
lesion in 7/9 (78 %) mutated cases. Thereby, the allele
frequency of the RAS mutations varied between primarytumour, liver and/or lung metastases. In two cases, the
allele frequencies were below 10 % in the synchronous
liver metastasis (9.7 %, case #5) and in one of the two
synchronous lung metastastic lesions (5.6 %, case
#13). In cases #3 and #6, the KRAS p.G12V mutation
was not detected in the metachronous lung and liver
metastasis even at a cut-off level of >1 % allele fre-
quency. The drop of allele frequency in mainly small
metastatic lesions most likely relates to the limited or
only single distributed (e.g. case #6 liver metastasis,
Fig. 2a) tumour cells available for microdissection.
Finally, none of the 5 cases with wildtype RAS in the pri-
mary tumour subsequently developed RAS mutations in the
EGFR-targeted therapy relevant “hotspot” codons (Table 3).Mutation profiles of CRC patients throughout the disease
course
To determine mutation profiles of tumour sites, respect-
ive locations of disease progression, we first examined
the NGS data sets of all 70 DNA samples in a case-
mixed manner.
This revealed tumour site associated shared sequence
variants in 1) APC, PDGFRA, PTEN for primary colon
and/or rectal tumours, 2) ATM, TP53 for synchronous
liver metastases, 3) FGFR3 and TP53 for metachronous
liver metastases, 4) ABL1, APC, ATM, ERBB4 and
SMAD4 for synchronous lung metastases, and 5) APC
and TP53 for metachronous lung metastases (Table 4).
Hence, this case-mixed analysis suggests some gene
sequence variants specific for liver or lung metastases,
but gives no information on whether or not these were
already present in e.g. the primary tumour of individual
CRC patients.Case-matched mutation profiles throughout disease
course reveal distinct de novo mutations in synchronous
versus metachronous lung metastases
Since the clinico-pathological parameters and disease
course are individual for each CRC patient (e.g. neoadju-
vant treatment in 4/5 rectal tumours as well as adjuvant
treatment regimens), we next analyzed the case-matched
mutation profiles, specifically focusing on the late(st)
stages of lung metastasis.
As shown by the Venn diagrams for each CRC case in
Fig. 3, generally few distinct mutations (maximum of 3, in-
cluding APC, KRAS, NRAS, PIK3CA, SMAD4 and/or
TP53) were shared between all case-matched DNA samples
(primary tumour, synchronous and/or metachronous liver
and/or lung metastases) of an individual CRC case (Table 2).
Taking into account the individual clinico-pathological pa-
rameters, there was no association of mutation profiles to
primary tumour site (left colon, right colon, rectum) or hist-
ology, tumour stage, grading or molecular subtype (Fig. 3).
Fig. 2 Morphology and tNGS amplicon coverage of investigated primary tumours and distant metastases of the CRC cases. a The panels depict
H&E sections of case-matched primary tumours, and synchronous and/or metachronous liver or lung metastasis of three representative cases.
Note areas of necrosis (“nec”; e.g. case #8, synM(HEP)) and widely distributed clusters of few tumor cells (e.g. case #6, metM(HEP)), necessary for interpretation
of gene mutations with lower allele frequencies. All panels same magnification 2.5x except case #6 metM(HEP) being 10x. b Summary of the amplicon
coverage for all 70 investigated DNA samples of the CRC cohort. Refer to the main text, Table 1 and Additional file 1: Table S2 for further details
Kovaleva et al. Molecular Cancer  (2016) 15:63 Page 9 of 19
Table 2 Summary of genes mutated in 2 or more case-matched tumour sites throughout disease course


















1 KRAS G12D G12D G12D
TP53 R342* WT R342*
2 APC Q1338* Q1338* Q1338* Q1338*
KRAS G12V G12V G12V G12V
SMAD4 R361C R361C R361C R361C
3 APC WT R1450* R1450* WT R1450*
R876* R876* R876* R876* R876*
KRAS G12V G12V WT G12V G12V
PIK3CA WT K111E WT WT K111E
TP53 R196* R196* R196* R196* R196*
4 TP53 R337C R337C R337C R337C
G199V G199V G199V G199V




PIK3CA E542K E542K E542K E542K
TP53 G244C G244C G244C G244C
6 APC Q1367* WT Q1367*
KRAS G12V WT G12V
SMAD4 Q250* WT Q250*
7 TP53 V157F V157F V157F V157F V157F
8 KRAS G13D G13D G13D G13D
TP53 R248Q R248Q R248Q R248Q
9 APC R1114* R1114* R1114* R1114* R1114*
TP53 R282W R282W R282W R282W R282W
10 APC T1556Nfs* T1556Nfs* T1556Nfs*
FGFR3 P718S P718H P718S
TP53 V157G V157G V157G
11 TP53 R273C R273C R273C R273C
12 APC WT L1488Tfs* L1488Tfs* L1488Tfs*











Table 2 Summary of genes mutated in 2 or more case-matched tumour sites throughout disease course (Continued)
13 ABL1 WT WT P315S P315S
APC R876* WT R876* WT
APC E1284* WT E1284* E1284*
ERBB4 WT WT D300N D300N
KRAS G12D p.G12V G12V (5.6 % AF) G12V
14 APC T1430Pfs* T1430Pfs* T1430Pfs* T1430Pfs*
NRAS Q61R Q61R Q61R Q61R




































53.59 89.98 47.32 32.82
3 KRAS
G12V
21.92 45.26 0 and
21.22
34
4 WT 0 0 0 0
5 KRAS
G12A




7 WT 0 0 0, 0
8 KRAS
G13D
34.16 50.44 31.43 12.85
9 WT 0 0 0 0
10 WT 0 0 0
11 WT 0 0 0
12 KRAS
G12A
99.74 56.72 34.15 19.63
13 KRAS
G12D, G12V
19.83 (G12D) 16.44 (G12V) 5.62a and 25.72
(G12V)
14 NRAS Q61R 44.31 66.91 and 44.74 46.17
The table summarizes the RAS status and mutated allele frequency (%) throughout the disease course of 9/14 mutated CRC cases. If two metastatic lesions were resected at the same time, the RAS status is given
for both











Table 4 Case-mixed analysis of tumour site specific mutations








ABL1 p.315S 0 0 0 2 0 0
APC p.R876* 2 0 0 0 0 3
p.R1114* 0 0 0 0 0 4
p.E1284* 0 0 0 2 0 0
p.Q1338* 0 0 0 2 0 0
ATM p.A1812V 0 0 2 0 0 0
ERBB4 p.D300N 0 0 0 2 0 0
FGFR3 p.T722I 0 0 0 0 2 0
PDGFRA p.P577S 1 1 0 0 0 0
PTEN p.Q171* 2 0 0 0 0 0
p.H185Y 1 1 0 0 0 0
SMAD4 p.R361C 0 0 0 2 0 0
TP53 p.W91* 0 0 0 0 0 2
p.175H 0 0 2 0 0 0
p.V157F 0 0 0 0 2 0
p.R196* 0 0 0 0 0 3
p.R282W 0 0 0 0 0 3
p.R273C 0 0 0 0 0 2
The table presents the gene variants detected in at least 2 samples per tumour site further to KRAS and NRAS, as analyzed in a case-mixed manner and with exclusion
of known SNPs
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mutations occurred in liver (cases #1, 2, 6, 7, 8, 10, 13)
and lung (cases #1, 2, 3, 6, 7, 8, 9, 10, 11, 12) metastases,
which were not present in the case-matched primary
tumours (Fig. 3): Case-matched analysis and comparison of
synchronous (n = 12 DNA samples of 11 CRC cases) versus
metachronous (n = 6 DNA samples of 5 CRC cases) liver
metastases yielded 4/12 (33 %) synchronous versus 4/6
(67 %) metachronous liver metastases with unique de novo
mutations. Thereby, the de novo mutation profiles
ranged from 1–90 and 2–20 variants in synchronous
as compared to metachronous liver metastases, including
mutations in FBXW7, FGFR3, GNAQ and PTEN
occurring in more than 2 cases with synchronous liver
metastases (Figs. 3 and 4a).
In contrast, case-matched analysis and comparison of
synchronous (n = 8 of 5 CRC cases) and metachronous
(n = 16 of 10 CRC cases) lung metastases revealed a
broad mutation profile in both synchronous (range of
variants: 21–90) and metachronous (range of variants:
1–98) lung metastases (Figs. 3 and 4b). Thereby, syn-
chronous lung metastasis more frequently showed muta-
tions in ATM, KIT, PIK3CA and SMAD4 (each with 3/5
cases as compared to 1/5 cases with metachronous liver
metastases). Moreover, metachronous lung metastases
showed exclusive mutations in CDKN2A, FGFR2, GNAS,
JAK3 and SRC (each 1/10 cases as compared to 0/5 caseswith synchronous lung metastases) as well as frequent
mutations in FBXW7 (4/10 cases; synchronous: 2/5
cases), SMO (3/10 cases; synchronous: 1/5 cases) and
STK11 (3/10 cases; synchronous: 1/5 cases).
As above, also the identified de novo mutations in lung
metastases were not associated with clinico-pathological
parameters. Thereby, neither the number of de novo mu-
tations and/or the genes affected by de novo mutations
were directly linked to specific prior treatment regimens,
as summarized in Table 5.
Hence, these data allow case-matched and tumour site
location specific identification of gene mutations in-
volved in disease progression of individual CRC cases.
Multiple lesions of lung, but not liver metastases resected
at one time point may differ in the mutation profile
Finally, de novo mutations in each two separate topo-
graphic lesions of liver or lung metastases of one re-
section in 3 CRC cases (#3, #13, #14) were examined
(Fig. 5):
Exactly the same mutation profile (mutations in APC,
NRAS, TP53) were detected in two lesions (liver seg-
ments 5 and 7) of the liver metastasis of case #14.
In contrast, in two lesions (upper, lower lobes) of the
synchronous lung metastasis of case #13 shared mutations
occurred in ABL1, APC, ATM and ERBB4, but this was
accompanied by 39 (“lower lobe left”) and 90 (“upper lobe
case #2 case #4 case #5




case #6 case #10 case #1
case #7 case #9
case #11
Fig. 3 Case-matched shared mutations in primary tumours and distant metastases of CRC cases. The panels depict Venn diagrams of variants detected per
case in primary tumour (blue), synchronous (yellow) and metachronous (orange) liver metastasis as well as synchronous (light green) and metachronous (dark
green) lung metastases. Numbers represent the number of sequence variants being shared (overlaps) or separate for a specific CRC tissue specimen. Note
that CRC cases #4, #5 and #14 exhibited mutations in the primary tumour, which were then also all detected in distant metastases and are hence only
depicted in the overlaps. Note three patterns of CRC cases: type I = cases #2, 4, 5, 8, 11, 12, 13, 14; type II = # 6, 10, 1 and type III = #3, 7, 9. These three types
did not correlate with the specific clinico-pathological or molecular features. Refer to main text for details
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A B
Fig. 4 De novo mutations detected in synchronous and metachronous liver and lung metastases. a The graph presents the number of CRC cases with de
novo mutations detected for all investigated 48 genes in synchronous (light grey; sM[HEP]) and metachronous (dark grey; mM[HEP]) liver metastases. b The
graph presents the number of CRC cases with de novo mutations detected for all investigated 48 genes in synchronous (light grey; sM[PUL]) and
metachronous (dark grey; mM[PUL]) lung metastases
Kovaleva et al. Molecular Cancer  (2016) 15:63 Page 15 of 19left”) additional variants for each separate lesion. Similarly,
in two lesions (lung segments 7 and 8) of the metachro-
nous lung metastasis of case #3 shared mutations were de-
tected in APC (n = 2), FGFR2 (n = 1) and TP53 (n = 1),
which was associated with 70 (“segment 7”) and 98
(“segment 8”) additional variants. Thereby, the different
mutation profiles of each the two lung metastatic lesions
per resection were seen for the mucinous (case #13) and
the tubular/NOS (case #3) CRC case (Fig. 5).Discussion
This study comprehensively evaluated the feasibility and
outcome of targeted next generation sequencing of case-
matched colorectal cancer (CRC) Formalin-fixed and
Paraffin-embedded tissue specimens in a close morpho-
logical context.
The study describes a novel protocol which allows
targeted next generation sequencing (tNGS) even from
low input and/or poorer quality DNA derived from
Table 5 De novo gene mutations in synchronous and metachronous lung metastasis in relation to treatment regimens
Case ID # syn/met Year of occurrence
post PT
Therapy regimen De novo mutations
1 met 5 Ardalan ABL1, FGFR3, KRAS, NRAS, RET, SMARCB1, STK11, TP53, VHL
3 met 2 FOLFOXIRI, FOLFOXIRI/Bevacizumab, Xeloda/
Bevacizumab, CAPIRI, Mitomycin, FOLFOX
AKT1, ALK, APC, ATM, CSF1R, EGFR, ERBB2, ERBB4, FBXW7,
FGFR2, FGFR3, FLT3, GNA11, GNAQ, HNF1A, IDH1, JAK3,
KDR, KIT, KRAS, MET, MLH1, NOTCH1, NPM1, NRAS,
PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMO,
SRC, STK11, TP53, VHL
4 met 2 FOLFOX, 5-FU/Mitomycin, FOLFIRI No de novo mutations
5 syn 2 3x FOLFOXIRI/Bevacizumab APC, ATM, FBXW7, FGFR3, KIT, KRAS, PIK3CA, PTEN, RB1,
SMAD4, TP53, VHL
6 met 5 3x FOLFIRI/Bevacizumab, FOLFOX SMO
7 met 5 FOLFOX4 No de novo mutations
8 syn,met 1,2 FOLFOXIRI, FOLFOXIRI/Bevacizumab FBXW7
9 met 4,5,7 Xeloda STK11, VHL, SMO, FBXW7, ERBB4, GNA11, PDGFRA
10 met 6 RCTx No de novo mutations
11 met 2,4 FOLFIRI/Bevacizumab PTEN, FBXW7
12 met 2 RCTx, Xeloda, FOLFIRI/Bevacizumab, FOLFIRI APC
14 syn 1 2x FOLFOXIRI/Bevacizumab, FOLFIRI/
Bevacizumab
ABL1, AKT1, APC, ATM, BRAF, CSF1R, CTNNB1, EGFR, ERBB2,
ERBB4, FGFR3, FLT3, GNA11, GNAQ, IDH1, KIT, MET, PIK3CA,
SMAD4, SMARCB1, TP53, VHL
The table summarizes de novo mutations per case in relation to occurrence of metastasis and treatment regimens. RCTx radio/chemotherapy, Syn synchronous,
met metachronous. Note that there is no direct correlation between specific treatment regimens and the number of de novo mutations and/or genes affected by
de novo mutations. Refer to main text for details
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using a sequencing-by-synthesis tNGS approach.
Moreover, the present study shows that mutation profil-
ing of CRC, respective investigation of “driver mutations”,
intratumoural heterogeneity and tumour evolution need
to be performed in a fully case-matched (i.e. taking into
account individual treatment regimens, including e.g.
neoadjuvant therapy of rectal cancers prior to resection of
the primary tumour) and morphology-controlled manner:
The spectrum of apparent “driver mutations” of e.g. lung
metastasis were different upon evaluation of all lung me-
tastases in a case-mixed manner as compared to analysis
of true “de novo” mutations of lung metastases in a case-
matched manner. In addition, the present study reveals an
obvious difference of the mutation profile in (case-
matched) synchronous and metachronous liver or lung
metastases, suggesting tumour heterogeneity and distinct
tumour evolution. Hence, the investigative approach of
the CRC cohort here focused on those mutations possibly
accounting for tumour progression of individual patients
more than 2 years post resection of the primary tumour.
The CRC cohort here only included 14 CRC patients, but
a total of 70 tissue specimens obtained during case-matched
follow-up, respective disease progression, especially resected
lung metastases, were investigated in a case-matched man-
ner also for tNGS data analysis and interpretation. Although
this appears a very small number of cases, this is in fact
similar in other CRC screening studies. For example, a largestudy of initially 2000 CRC patients, then selected 468 cases
for NGS and of these only 19 cases had matched metastases,
with 12/19 cases presenting distant metastases [19]. In other
studies, 13 cases with mainly liver metastases [13]; 24 cases
with either one (n= 7), two (n= 11) or three (n = 6) local or
distant metastatic lesions (lymph node, liver, lung, brain)
[17]; 16 rectal carcinomas with lymph node (n = 13/16), liver
(n= 1/16) or lung (n= 2/16) [16] were included. All of these
studies were performed by semi-conductor NGS technology
as compared to the present study using a sequencing-by-
synthesis tNGS approach. Few studies commented on the
morphological aspects of the (microdissected?) tumour
specimens in case when allele frequencies drop, which
may merely be due to few (enriched?) tumour cells
from CRC tissue specimens (e.g. especially in neoadju-
vant treated primary rectal tumours or highly necrotic
liver metastases). Clearly, statistical sub-group analyses
in such a small cohort are not feasible to address all of
these clinico-pathological factors. Hence, the present
study reports on and presents case-matched tNGS re-
sults with associated clinico-pathological data and mor-
phological observations.
In fact, our present study addresses the morphological
aspect from different angles: First, by precise microdis-
section under a microscope using fine needles we clearly
eliminate e.g. lymphocyte-rich or necrotic areas from
DNA sample preparation. Second, we provide the tumour
cell content in terms of the percent of enriched (tumour)
Fig. 5 Morphology of case-matched separate CRC metastatic liver or lung lesions resected at one time point with similar or distinct mutation profiles.
The panels show H&E stainings of primary tumours and their associated resected liver or lung metastases, from which each two topographically distant
located separate lesions (labelled lesion A and lesion B) were individually analyzed by tNGS. Case # 14 showed the same mutation profile in the primary
tumour and its associated two metastatic liver lesions (within segments 5 and 7). Cases #13 (upper, lower lobes of lung) and cases #3 (segments 7 and 8)
each showed only few shared mutations and numerous additional mutations associated with either of the individual lung metastatic lesions, despite similar
morphology. Refer to main text for details
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feasible approach that is applicable to routine molecular
pathology diagnostics – the initial diagnostic biopsy or re-
section specimen is used (not a separate tissue specimen
obtained just for molecular analysis by an invasive
approach, which is frequently impossible in advanced
disease stages of CRC and other solid tumours) and
all data interpretation is made with respect to the
morphology, as specifically shown for the selected
multiple distant metastatic tumour lesions of single
resection specimens.
In this setting, we first report on the findings of the
RAS mutation status by tNGS in the CRC cohort, with
9/14 cases showing known KRAS or NRAS mutations.
Thereby, mutation status was maintained throughout
the disease course albeit with altered allele frequencies.
In fact, 2/9 cases showed a RAS mutation in the primary
tumour, which was apparently “lost” at first sight in their
metastases. Careful evaluation of the morphology clearly
showed only few tumour cells available for DNA extrac-
tion in serial sections of the tissue specimens, which
without morphological controlled enrichment might
have been diluted in “non-tumour cell (and necrotic)
background”. However, a morphology-adapted tNGS
cut-off to lower allele frequencies then indeed showed
RAS mutations at <5 % in the 2/5 cases. Similarly,observations were reported in a previous study for KRAS
and other gene mutations [17], however no reference
was made as to the morphology of these lesions, which
in liver and lung tend to be highly necrotic with a pau-
city of tumour cells for enrichment by microdissection.
Hence, the present data validates mutations in genes
(e.g. APC, KRAS, NRAS, TP53) known to be involved in
(sporadic) CRC development and throughout progres-
sion [13, 16, 17, 27] with close reference to the clinico-
pathological features. In fact, these key mutations, here
referring to the exact sequence variant, were not directly
associated with the primary tumour location (left or
right colon, rectum) and histology, tumour stage, grad-
ing or molecular sub-type (Microsatellite-(in)stability;
CpG-Island methylator phenotype) in this small cohort.
Moreover, in the present study only a maximum of 3 se-
quence variants were shared between all CRC tumour
sites throughout disease progression upon case-matched
analyses, whereas broader and new mutation profiles
were seen especially upon tumour progression to (syn-
chronous or metachronous) lung metastases. The lim-
ited overlap of shared sequence variants between
primary CRC and multiple metastatic lesions was not re-
ported before. However, also others showed the same
few genes to be similarly affected in primary tumours
and associated distant metastases [13, 15, 17, 19].
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tions occurring in liver or lung metastases of case-matched
tumours in at least 3 cases were in APC, ATM, FBXW7,
FGFR3, GNAQ, KIT, PIK3CA, PTEN, SMAD4, SMO,
STK11, TP53 and VHL. Thereby, synchronous vs metachro-
nous as well as liver vs lung metastases displayed distinct
gene patterns suggesting distinct tumour evolution. Of
these, several mutations may be actionable through targeted
therapies interfering with the affected signaling pathways,
e.g. FBXW7 (Additional file 1: Figure S2) (this study and
[14, 16, 17, 28–30]) and its functional consequences on
mTOR and PTEN signaling [31–33] and mTOR inhibitors
[34]. These data suggest that when looking at advanced
disease stages of CRCs, each patient needs to be individually
addressed due to the case-specific prior surgical and clinical
treatment regimens and associated case-specific molecular
progression. Hence, sequential biopsies – if clinically pos-
sible – or accompanying liquid biopsies may eventually
evolve as supplementary tool to SOP-driven molecular tis-
sue based analyses for defining individual treatment options.
Conclusion
Together, our present study demonstrates a novel
approach for targeted next generation sequencing of rou-
tine diagnostic FFPE tissue specimens and thereby again
highlights the importance of morphological-controlled tis-
sue specimens. By this, the study identifies only few shared
mutations, respective exact sequence variants throughout
the disease course of individual colorectal cancer patients,
including KRAS and NRAS. Furthermore, the study shows
case-matched de novo altered mutation profiles in syn-
chronous vs metachrounous liver and/or lung metastasis.
Some of the affected genes - e.g. FBXW7 and PTEN may
thereby be further explored for targeted therapy, including
validation of findings in larger prospective case series.
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